the aid library

LIST OPTIONS

Filter

8592

Management of the sick young infant aged up to 2 months. Participant Manual
recommended

World Health Organization WHO (2019) C_WHO

Integrated management of childhood illness. The last update was in the IMCI chart booklet in 2014, but since then there have been significant updates on the management of sick young infant (SYI) aged up to 2 months. This 2019 update of the sick young infant section Management of the sick young infan... more

Download (302)

View PDF (217)

Lista de dispositivos médicos prioritarios para el primer nivel de atención en los países de la Región de las Américas. Tercera versión, noviembre del 2021

Organización Mundial de la Salud OMS OPS (2021) C_WHO

La Organización Panamericana de la Salud publica la tercera versión de la lista de dispositivos médicos prioritarios (LDMP) para el primer nivel de atención, elaborada de acuerdo con la realidad epidemiológica de los países de la Región de las Américas y adaptada al contexto de la pandemia d... more

Download (648)

View PDF (245)

Integrated Management of Childhood Illness (IMCI) - 2019 (Updated)

National Department of Health South Africa National Department of Health South Africa (2019) CC

Integrated Management of Childhood Illness (IMCI) is an integrated approach to child health that focuses on the holistic well-being of the child. IMCI aims to reduce death, illness and disability, and to promote improved growth and development among children under five years of age. IMCI includes bo... more

Download (218)

View PDF (286)

Target product profile for a rapid test for diagnosis of Buruli ulcer at the primary health-care level

World Health Organization WHO (2022) C_WHO

In 2009, WHO’s Second International Conference on Buruli Ulcer Control and Research resolved to strengthen the capacity of national laboratories to confirm cases of the disease, but advised that “efforts are still needed to develop simple diagnostic tools usable in the field as well as disabilit... more

Updated recommendations on simplified service delivery and diagnostics for hepatitis C infection
recommended

World Health Organization WHO (2022) CC

Policy Brief. 24 June 2022. This policy brief, one of two on the updated hepatitis C (HCV) guidelines, focuses on the new recommendations on simplified service delivery for a public health approach to HCV testing, care and treatment. These recommend... more

Download (190)

View PDF (379)

Product profile for a rapid test for diagnosis of Buruli ulcer at the primary health-care level

Diagnostics Technical Advisory Group (DTAG) World Health Organization WHO (2022) C_WHO

In 2013, WHO and the Foundation for Innovative New Diagnostics convened a meeting of Buruli ulcer experts in Geneva, Switzerland (9) at which two priority unmet needs in diagnosis were identified: a diagnostic test for early detection of Buruli ulcer in symptomatic patients with sufficient positive... more

Download (151)

View PDF (188)

Antimicrobial Resistance in Food-Animal Production INDIA OVERVIEW

Action on Anitbiotic Resistance (ReAct) (2018) C2

Indian markets caused a stir across the country.1 According to the Centre for Science and the Environment (CSE), a respected New Delhi-based NGO, most honey brands sold in India contained varying amounts of antibiotics. Their consumption over time could induce resistance to antibiotics, putting p... more

Download (235)

View PDF (225)

Manual for case management of cutaneous leishmaniasis in the WHO Eastern Mediterranean Region

World Health Organization WHO WHO Regional Office for the Eastern Mediterranean (2014) CC

This publication represents a key step forward in translating Control of the leishmaniases (WHO Technical Report Series, No. 949) into a more practical tool for health personnel directly involved in the case management of cutaneous leishmaniasis. With this manual, countries will have, for the first ... more

Download (121)

View PDF (167)

Gambiense human African trypanosomiasis: the bumpy road to elimination

Hasker E, Hope A, Bottieau E. Wolters Kluwer Health, Inc. (2022) C2

Gambiense human African trypanosomiasis is a deadly infectious disease affecting West and Central Africa, South Sudan and Uganda, and transmitted between humans by tsetse flies. The disease has caused several major epidemics, the latest one in the 1990s. Thanks to recent innovations such as rapid di... more

External Link

Report of the first WHO stakeholders meeting on rhodesiense human African trypanosomiasis Geneva, 20–22 October 2014

World Health Organization WHO (2014) C_WHO

The objectives of the meeting were: 1. To update the current status of the disease transmission, country capacities and plans for tackling the disease. 2. To understand the epidemiology including disease distribution and risk, the models for estimating under-detection, the geographical variati... more

Download (185)

View PDF (197)

WHO European Centre for Primary Health Care: annual report 2022

World Health Organization WHO (2023) C_WHO

This report describes the activities of the WHO European Centre for Primary Health Care in 2022.The Centre accelerated face-to-face country support after the wake of the COVID-19 pandemic to support countries in engaging in analysis and diagnosis, developing strategies and policies, building capacit... more

Download (206)

View PDF (200)

How to support survivors of gender-based violence when a GBV actor is not available in your area

Inter-Agency Standing Committee (2023) CC

KEY MESSAGES Always talk to a GBV specialist first to understand what GBV services are available in your area. Some services may take the form of hotlines, a mobile app or other remote support. Be aware of any other available services in your area. Identify services provided by humanitarian pa...rtners such as health, psychosocial support, shelter and non-food items. Consider services provided by communities such as mosques/ churches, women’s groups and Disability Service Organizations. Remember your role. Provide a listening ear, free of judgment. Provide accurate, up-to-date information on available services. Let the survivor make their own choices. Know what you can and cannot manage. Even without a GBV actor in your area, there may be other partners, such as a child protection or mental health specialist, who can support survivors that require additional attention and support. Ask the survivor for permission before connecting them to anyone else. Do not force the survivor if s/he says no. Do not proactively identify or seek out GBV survivors. Be available in case someone asks for support. Remember your mandate. All humanitarian practitioners are mandated to provide non-judgmental and non-discriminatory support to people in need regardless of: gender, sexual orientation, gender identity, marital status, disability status, age, ethnicity/tribe/race/religion, who perpetrated/committed violence, and the situation in which violence was committed. Use a survivor-centered approach by practicing: Respect: all actions you take are guided by respect for the survivor’s choices, wishes, rights and dignity. Safety: the safety of the survivor is the number one priority. Confidentiality: people have the right to choose to whom they will or will not tell their story. Maintaining confidentiality means not sharing any information to anyone. Non-discrimination: providing equal and fair treatment to anyone in need of support. If health services exist, always provide information on what is available. Share what you know, and most importantly explain what you do not. Let the survivor decide if s/he wants to access them. Receiving quality medical care within 72 hours can prevent transmission of sexually transmitted infections (STIs), and within 120 hours can prevent unwanted pregnancy. Provide the opportunity for people with disabilities to communicate to you without the presence of their caregiver, if wished and does not endanger or create tension in that relationship. If a man or boy is raped it does not mean he is gay or bisexual. Gender-based violence is based on power, not someone’s sexuality. Sexual and gender minorities are often at increased risk of harm and violence due to their sexual orientation and/or gender identity. Actively listen and seek to support all survivors. Anyone can commit an act of gender-based violence including a spouse, intimate partner, family member, caregiver, in-law, stranger, parent or someone who is exchanging money or goods for a sexual act. Anyone can be a survivor of gender-based violence – this includes, but isn’t limited to, people who are married, elderly individuals or people who engage in sex work. Protect the identity and safety of a survivor. Do not write down, take pictures or verbally share any personal/identifying information about a survivor or their experience, including with your supervisor. Put phones and computers away to avoid concern that a survivor’s voice is being recorded. Personal/identifying information includes the survivor’s name, perpetrator(s) name, date of birth, registration number, home address, work address, location where their children go to school, the exact time and place the incident took place etc. Share general, non-identifying information To your team or sector partners in an effort to make your program safer. To your support network when seeking self-care and encouragement. more

Download (145)

View PDF (176)

Are donors targeting the greatest health needs? Evidence from mining sites in the D.R.Congo

S. Lordemus AidData at William & Mary (2019) CC

I examine the effectiveness of donors in targeting the highest burden of malaria in the Democratic Republic of Congo when health information structure is fragmented. I exploit local variations in the burden of malaria induced by mining activities as well as financial and epidemiological data from he... more

Download (178)

View PDF (194)

Colaboración entre el sector de WASH y el sector de la salud: Guía práctica para los programas de lucha contra las enfermedades tropicales desatendidas. Segunda edición corregida
recommended

Organización Mundial de la Salud OPS (2023) C_WHO

La atención concedida a la equidad en la Agenda 2030 para el Desarrollo Sostenible obliga a encontrar nuevas formas de ampliar progresivamente los servicios a las poblaciones que no los reciben. Las alianzas satisfactorias entre el sector encargado del suministro de agua, el saneamiento y la higien... more

Download (290)

View PDF (386)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

External Link

Screening for cardiovascular disease risk and subsequent management in low and middle income countries: challenges and opportunities

Bovet, P.; Chiolero, A.; Paccaud, F. et al. Public Health Reviews (2015) CC

Background: Cardiovascular disease (CVD), mainly heart attack and stroke, is the leading cause of premature mortality in low and middle income countries (LMICs). Identifying and managing individuals at high risk of CVD is an important strategy to prevent and control CVD, in addition to multisector... more

WHO package of essential noncommunicable (PEN) disease interventions for primary health care

World Health Organization (WHO) World Health Organization (WHO) (2020) C_WHO

The "WHO Package of Essential Noncommunicable (PEN) Disease Interventions for Primary Health Care" provides a set of cost-effective, evidence-based interventions to address noncommunicable diseases (NCDs) such as cardiovascular diseases, diabetes, chronic respiratory diseases, and cancers. Designed ... more

Task-shifting to improve asthma education for Malawian children: a qualitative analysis

Nkhalamba, L.; Rylance, S.; Muula, S. A. et al. Human Resources for Health (2021) CC

Background Asthma education, a key component of long-term asthma management, is challenging in resource-limited settings with shortages of clinical staff. Task-shifting educational roles to lay (non-clinical) staff is a potential solution. We conducted a randomised controlled trial of an enhanced a... more

External Link

Cardiovascular, Respiratory, and Related Disorders. Disease Control Priorities, Third Edition : Volume 5

rabhakaran, Dorairaj; Anand, Shuchi; Gaziano, Thomas A.; et al. World Health Organisation (WHO) (2017) CC

This volume on CVDs, renal, and respiratory disorders has particularly high value. It carries the potential to become the most effective game-changer in global health by helping all countries to combat, contain, and control the biggest killer presently prowling the globe and by enabling us to reach ... more

Download (157)

View PDF (203)

Agenda for the Americas on Health, Environment, and Climate Change 2021–2030

Pan American Health Organization (2021) C_WHO

This publication presents the Agenda for the Americas on Health, Environment, and Climate Change 2021–2030 (the Agenda). The Agenda is a call to action to the health sector to lead the charge to address environmental determinants of health in the Americas. The Pan American Health Organization (PAH...O) will work with Member States to achieve its goal and objective to ensure healthy lives and promote well-being for all at all ages using a sustainable and equitable approach that places a priority on reducing health inequity. The Agenda has been developed under the umbrella of the WHO Global Strategy on Health, Environment, and Climate Change, and builds upon the commitments set forth in the Sustainable Health Agenda for the Americas 2018–2030 and the PAHO Strategic Plan 2020–2025. The Agenda was developed in consultation with the Technical Advisory Group and through a consensus-driven decision-making process with Member States during the 2019–2020 period. Looking toward the achievement of Sustainable Development Goal 3, the Agenda focuses on: improving the performance of environmental public health programs and institutions; fostering environmentally resilient and sustainable health systems; and promoting environmentally healthy and resilient cities and communities. Its implementation will be context-specific, based on the needs and realities of the countries. It will benefit countries and territories by promoting good governance practices, strengthening the leadership and coordination roles of the health sector, fostering cross-sectoral action, focusing on primary prevention, and enhancing evidence and communication. It will facilitate access to human, technical, and financial resources necessary to address environmental determinants of health and ensure that the Region is fully engaged in global health, environment, and climate change processes and agreements. The objective of the Agenda is to strengthen the capacity of health actors in the health and non-health sectors to address and adapt to environmental determinants of health (EDHs), prioritizing populations living in conditions of vulnerability, in order to meet Outcome 18 of the PAHO Strategic Plan 2020–2025 directly and several other outcomes of the Plan indirectly. To address and adapt to the challenges of EDHs in the Region, an integrated and evidence-informed approach within the health sector and across sectors will be needed, one enabled, and supported by good governance practices, adequate management mechanisms, high-level political will, and adequate human, technical, technological, and financial resources. more

Management of the sick young infant aged up to 2 months. Participant Manual recommended

Updated recommendations on simplified service delivery and diagnostics for hepatitis C infection recommended

Colaboración entre el sector de WASH y el sector de la salud: Guía práctica para los programas de lucha contra las enfermedades tropicales desatendidas. Segunda edición corregida recommended

Management of the sick young infant aged up to 2 months. Participant Manual
recommended

Updated recommendations on simplified service delivery and diagnostics for hepatitis C infection
recommended

Colaboración entre el sector de WASH y el sector de la salud: Guía práctica para los programas de lucha contra las enfermedades tropicales desatendidas. Segunda edición corregida
recommended